We are thrilled to announce the launch of our new Lyme VlsE Assay, a cutting-edge diagnostic tool powered by our proprietary Epitogen® technology. This breakthrough assay marks a significant advancement in the fight against Lyme disease by enabling both strain-level identification and enhanced diagnostic sensitivity. Using Epitogen®, we [...]
We are thrilled to announce that Vertebrate Antibodies, in collaboration with the University of Aberdeen, has won a Scottish Knowledge Exchange Award 2024! This esteemed recognition highlights our pioneering work in AI-driven diagnostics and precision medicine, showcasing the power of industry-academia partnerships. Our collaboration with the University of Aberdeen has been instrumental in [...]
Immune memory, from either infection or immunization, is the source of long-term protective immunity. Antibodies are a key component of immune memory that can provide protection. The spike protein is the focus of most COVID-19 vaccines. Antibody responses to the spike protein and other viral proteins can [...]
Universal EpitoGen® SARS-CoV-2 ELISA assay At a population level, the humoral response to SARS-CoV-2 is heterogeneous. In the course of our development of EpitoGen SARS-CoV-2 assays we observed that significant numbers of samples were only reactive for either the Spike or Nucleocapsid antigen alone. Therefore, traditional [...]
EpitoGen Technology and AiBiologics machine learning software (EpitopePredikt) were employed to develop a set of unique, highly sensitive SARS-Cov-2 ELISA assays. EpitopePredikt was used to scan SARS-CoV-2 antigen and identify immunodominant epitopes. The epitopes were then expressed in combination using EpitoGen Technology and validated for detection of [...]
EpitoGen Technology is a novel epitope/peptide expression platform. The epitope antigen (Epitogen) is fused in the middle of an inert scaffold protein and displayed on the top of the scaffold ideally suited to a number of antigen/antibody-based assays such as ELISA and lateral flow. The technology was [...]
4th October 2019 VAL is pleased to confirm the appointment of Richard Atkins as Director of Commercialisation. He will lead the marketing and business development of VAL’s projects. About Richard Atkins For over 30 years Richard has become very commercially driven with significant strategic, communication and growth [...]
1st October 2019 VAL is pleased to confirm the appointment of Dr Tiehui Wang as Director of Biologicals. He will be the head of the Recombinat Division and generate active proteins for research and animal health. About Dr Tiehui Wang Dr Tiehui Wang is a leading immunologist [...]
The Journal of Pathology An abstract of the work presented at the Leeds Pathology Conference (2-4 July, 2019) has now been published in The Journal of Pathology, Volume 249 (Issue S1) Page S56. The supplement can be accessed through Wiley Online Library( WOL) View the abstract here. [...]
As part of Vertebrate Antibodies Ltd (VAL)’s ongoing expansion, the company has vacancies for new jobs in Aberdeen such as this one for a Research Assistant. VAL is a rapidly developing biotech company with a wealth of experience in developing high performance antibodies and their modified [...]
